News
THE CENTER FOR BIOMEDICAL RESEARCH EXCELLENCE ON OBESITY AND CARDIOVASCULAR DISEASES (COCVD) FUNDING OPPORTUNITY
Of the 14 million cancer survivors in the United States, a significant number experience a serious side effect called chemotherapy-induced cognitive impairment (CICI). While easily recognized, little is known about the etiology of this condition, also known informally as “chemo brain.” CICI can significantly reduce patients’ quality of life with serious, even devastating, symptoms such as memory lapses, difficulty concentrating, negative impacts on multitasking, confusion and fatigue.
Recently, UK Research Financial Services, formerly called Sponsored Projects Accounting, made a few changes to the PI financial reports they provide through email each month to all PIs. In response to those changes, the College of Medicine Sponsored Research Administrative Services (SRAS) created a helpful information document to assist you in working with the new financial report. To access the Best Practices Document, click here.
The Office of Technology Commercialization recently published is 2017 Annual Report, detailing the commercialization achievements of the office as well as the new programs, resources and services that it offers. Click on the document below to see the full report.
NIH recently issued a notice to remind both applicants and program officials that all applications must be complete and compliant at the time of submission.
Applications can not contain placeholder documents to override the eRA system checks.
Applicants are responsible for completing checks for errors and omissions prior to 5PM local time on the application date.
We would like to inform you about a new initiative called OnPAR (Online Partnership to Accelerate Research). This was launched by Leidos Life Sciences
Epidemiologist Dr. Camara Phyllis Jones will present the next installment of the University of Kentucky College of Medicine Dean's Distinguished Lecture Series, "Achieving Health Equity: Tools for a National Campaign Against Racism."
Jones is research director on social determinants of health and equity for the U.S. Centers for Disease Control and Prevention. She is a family physician and epidemiologist whose work focuses on the impact of racism on the health and well-being of the nation.
The 2017 Annual Kentucky Neuroscience Clinical-Translation Research Symposium is a day-long event that will provide the opportunity for basic, translational and clinical neuroscience investigators including trainees, laboratory and program directors throughout the university to discuss their work, share progress and develop collaborations. The 2nd annual event is now open for registration and accepting abstract submissions a
On August 31, 2017, NIH released its updated policy promoting growth, stability and diversity in the biomedical research workforce. NIH acknowledges that early career scientists have found it increasingly difficult to obtain research funding for their first award. To address the increased difficulty, NIH will require that institutes prioritize awards for scientists early in their careers.
The Kentucky Research Data Center (KRDC) is now open on UK’s campus. The facility offers researchers with approved projects the opportunity to access restricted data from the Census Bureau, the Bureau of Labor Statistics, and the Centers for Disease Control and Prevention. The Center is located in Suite 125A of the Gatton College of Business and Economics. Because the KRDC is a high security federal statistical research data center, those interested in conducting work at the facility must undergo a project review and obtain security clearance to access the Center.
Several new features will be added to xTRACT in a software release scheduled for Thursday, August 24, 2017. xTRACT is the Extramural Trainee Reporting and Career Tracking system and is accessed via eRA Commons. It allows applicants, grantees and assistants to create research training tables for progress reports and institutional training grant applications.
The Graduate School Tuition Fee Schedule was updated recently. The FY 2017/2018 acutal universal tuition rate for a full-time GA/RA is $12,246 ($6,123 per semester); and the actual health insurance premium is $2,166 ($823 – fall semester, and $1,343 – spring semester).
For more information, click here.
Consistent with the University of Kentucky’s (UK) mission, vision, and values, the Office of the Vice President for Research (VPR) provides programs and services to facilitate research, as well as support UK faculty, staff and students in research development and submission.
The UK Proposal Development Office (PDO) is a pre-award resource within the suite of services provided by the Office of the Vice President for Research to support strategic research development across campus through targeted resource and service delivery. PDO provides an array of services to faculty, staff, and students to assist them in securing extramural funding for scholarly activities. Primary research development services include:
coordination of complex multi-disciplinary projects and proposals;
[from the NIH website]
Message to NIH grant applicants/awardees, contractors, researchers and research administrators:
If you are conducting NIH-funded research that involves human subjects, or are considering applying to NIH for support of such research, we want to call your attention to important changes that may affect how you:
On August 2, 2017, NIH released an updated policy eliminating appendix material related to clinical trials for applications submitted to the NIH, AHRQ or NIOSH for due dates on or after January 25, 2018. The new policy specifies that all information for the peer review process must be contained within the application itself, in the designated section.
A new study by University of Kentucky Markey Cancer Center researchers shows that when therapy-sensitive cancer cells die, they release a "killer peptide" that can eliminate therapy-resistant cells.
Tumor relapse is a common problem following cancer treatment, because primary tumor cells often contain therapy-resistance cancer cells that continue to proliferate after the therapy-sensitive cells have been eliminated.